종양학 정보 시스템(OIS) 시장 : 예측(2026-2031년)

Oncology Information Systems Market is expected to grow at a 7.06% CAGR, increasing from USD 3.184 billion in 2025 to USD 4.795 billion in 2031.

The oncology information systems (OIS) market comprises specialized software platforms designed to manage the complex, data-intensive, and multidisciplinary workflow of cancer care. These systems function as the central nervous system of modern oncology practices, integrating patient data, treatment planning, scheduling, and outcomes tracking to support clinical decision-making, operational efficiency, and compliance in a high-stakes therapeutic area.

Core System Function and Clinical Integration

An OIS is not a singular application but an integrated suite of modules tailored to oncology's unique demands. Core functionalities typically include patient scheduling, electronic medical records (EMR) with oncology-specific templates, chemotherapy order entry and management (CPOE), radiation therapy planning and record-keeping, clinical trial management, and outcomes analysis. Its fundamental value lies in creating a unified patient record across the care continuum-from diagnosis and staging through surgery, radiation, systemic therapy, and survivorship-ensuring coordination among surgical, medical, and radiation oncologists, nurses, pharmacists, and dosimetrists.

Primary Market Growth Drivers

Market expansion is fundamentally driven by the rising global burden of cancer, which increases the volume and complexity of patient management. A growing caseload necessitates scalable, efficient systems to minimize errors, standardize care pathways, and manage the intricate logistics of treatment cycles, fueling demand for robust OIS solutions.

The rapid evolution of cancer therapeutics is a powerful catalyst for OIS adoption and sophistication. The shift toward personalized medicine, biomarker-driven therapy, and complex multimodal regimens (combining radiation, immunotherapy, and targeted agents) generates vast, heterogeneous data. Modern OIS platforms are essential for managing this complexity, tracking genomic results, calculating precise drug doses and radiation plans, and ensuring the safe administration of novel agents with unique toxicity profiles.

Technological convergence is a key growth vector. Advancements in interoperability standards (e.g., HL7, FHIR), cloud computing, and data analytics are transforming OIS capabilities. Integration with diagnostic imaging (PACS), laboratory systems, and genomic databases creates a holistic patient view. The incorporation of artificial intelligence and machine learning for tasks like auto-contouring in radiation planning, predictive analytics for patient risk stratification, and clinical decision support is moving OIS from administrative tools to intelligent clinical aids.

The structural shift toward value-based and outcomes-focused cancer care models reinforces the need for sophisticated data capture and analysis. OIS enables the aggregation of real-world evidence, tracking of quality metrics, and reporting required by payers and tumor registries, making it indispensable for demonstrating care quality and cost-effectiveness.

The integration of telemedicine and remote monitoring capabilities, accelerated by recent healthcare delivery trends, has become a critical feature. OIS platforms now support virtual consultations, remote patient-reported outcome (PRO) collection, and telehealth coordination, extending the reach of oncology expertise and facilitating continuous care management outside the clinic.

Market Restraints and Implementation Challenges

The market faces significant barriers related to system integration and resource constraints. Implementing and maintaining an OIS requires substantial capital investment, dedicated IT support, and extensive user training. Integrating the OIS with a hospital's existing enterprise EHR, pharmacy, and billing systems is often a complex, time-consuming, and costly undertaking, potentially leading to workflow disruptions.

Furthermore, disparities in healthcare infrastructure can limit adoption. Resource-constrained or rural facilities may lack the financial means, reliable high-speed internet, or specialized IT personnel required for advanced OIS platforms, creating a digital divide in access to these operational tools.

Geographic Landscape and Adoption Patterns

North America represents a mature and dominant market, characterized by high cancer care expenditure, early adoption of digital health technologies, and a complex regulatory and reimbursement environment that necessitates robust data management. The presence of leading OIS vendors, integrated cancer networks, and significant investment in healthcare IT consolidates the region's leadership.

Other developed regions and select high-growth markets are also advancing adoption, driven by national cancer control plans, investments in centralized cancer centers, and the need to improve care coordination and data collection for research and public health monitoring.

Competitive Landscape and Strategic Evolution

The competitive environment includes specialized oncology software firms and large healthcare IT corporations with dedicated oncology divisions. Differentiation is achieved through depth of clinical functionality-particularly in advanced radiation therapy planning and complex systemic therapy management-seamless interoperability, user experience, and robust analytics and reporting modules.

Strategic initiatives focus on developing cloud-native platforms to reduce IT burden on clinics, expanding AI-powered clinical tools, and creating modular systems that can scale from community practices to large academic centers. Partnerships with pharmaceutical companies and clinical research organizations to streamline trial recruitment and data management are also a growing strategic focus.

Future Market Trajectory

The future trajectory of the OIS market is oriented toward greater intelligence, interoperability, and patient-centricity. OIS will evolve into predictive clinical operating systems, leveraging aggregated data to suggest personalized treatment pathways and identify patients at risk for complications or hospital readmission.

Enhanced patient portals and mobile integration will empower patients as active participants in their care. Furthermore, the role of OIS in enabling decentralized clinical trials and real-world evidence generation will expand significantly. Success for vendors will hinge on demonstrating a clear return on investment through improved operational efficiency, enhanced patient safety, and support for high-quality, coordinated care. As oncology becomes increasingly data-driven and multimodal, the OIS market is poised for sustained growth as the essential digital infrastructure underpinning effective, efficient, and equitable cancer care delivery.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Oncology Information Systems Market Segmentation:

• By Product
• Solutions
• Professional Services
• By Application
• Medical Oncology
• Radiation Oncology
• Surgical Oncology
• By End-User
• Hospitals & Diagnostic Imaging Centers
• Government Institutions
• Research Facilities
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. ONCOLOGY INFORMATION SYSTEMS MARKET, BY PRODUCT

• 5.1. Introduction
• 5.2. Solutions
• 5.3. Professional Services

6. ONCOLOGY INFORMATION SYSTEMS MARKET, BY APPLICATION

• 6.1. Introduction
• 6.2. Medical Oncology
• 6.3. Radiation Oncology
• 6.4. Surgical Oncology

7. ONCOLOGY INFORMATION SYSTEMS MARKET, BY END-USER

• 7.1. Introduction
• 7.2. Hospitals & Diagnostic Imaging Centers
• 7.3. Government Institutions
• 7.4. Research Facilities

8. ONCOLOGY INFORMATION SYSTEMS MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. Varian
• 10.2. RaySearch Laboratories
• 10.3. Seimens Healthineers
• 10.4. Elekta
• 10.5. Chiuhomed
• 10.6. Mckesson
• 10.7. IQVIA
• 10.8. Cerner
• 10.9. Philips
• 10.10. GE Healthcare